What is Aliskiren Used For?
Aliskiren is a direct renin inhibitor indicated for the treatment of hypertension in adults and pediatric patients weighing ≥50 kg who are at least 6 years of age, with the goal of lowering blood pressure to reduce the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions 1.
Mechanism and Clinical Role
Aliskiren works by directly inhibiting renin at the first step of the renin-angiotensin-aldosterone system (RAAS) cascade, blocking the conversion of angiotensinogen to angiotensin I, which subsequently reduces angiotensin II formation 1. This represents a distinct mechanism compared to ACE inhibitors and ARBs, which act further downstream in the RAAS pathway.
Approved Indications
Primary Use: Hypertension
- Starting dose: 150 mg once daily (adults and pediatric patients ≥50 kg)
- Titration: May increase to 300 mg daily if blood pressure remains uncontrolled
- Timing: Majority of antihypertensive effect achieved within 2 weeks 1
- Can be used as monotherapy or in combination with other antihypertensive agents 1
Critical Contraindications and Warnings
Absolute Contraindications
- Do NOT combine with ACE inhibitors or ARBs in patients with diabetes 1
- Hypersensitivity to any component
- Pediatric patients <2 years of age 1
Major Safety Concerns from Guidelines
The 2025 AHA/ACC Hypertension Guidelines explicitly warn against dual RAAS blockade: High-quality RCT evidence demonstrates that simultaneous administration of RAS blockers (ACEi + ARB, or ACEi/ARB + aliskiren) increases the risk of cardiovascular disease, kidney disease, and hyperkalemia 2, 3. This represents a Class III recommendation (harm).
Additional Warnings
- Avoid concomitant use with ACEis or ARBs, particularly in patients with renal impairment (CrCl <60 mL/min) 1
- Fetal toxicity: Boxed warning for pregnancy - discontinue immediately when pregnancy detected 1
- Monitor for anaphylactic reactions and angioedema 1
- Risk of hypotension, especially in volume/salt-depleted patients 1
- Monitor serum creatinine and potassium levels periodically 1
Drug Interactions to Avoid
- Cyclosporine or itraconazole: Avoid concomitant use 1
- NSAIDs: Increased risk of renal impairment and loss of antihypertensive effect 1
- Ketoconazole: Significantly increases aliskiren blood levels 1
Clinical Context
While aliskiren is FDA-approved for hypertension, current guideline recommendations do not favor it as a first-line agent. The 2025 AHA/ACC guidelines do not list direct renin inhibitors among preferred initial antihypertensive classes, and specifically caution against combining aliskiren with other RAAS blockers due to increased harm 2, 3.
The drug may be considered when patients are intolerant to first-line therapies (thiazide diuretics, ACE inhibitors, ARBs, calcium channel blockers), but its role has been limited by safety concerns from large trials showing increased adverse events with dual RAAS blockade.
Common Pitfalls
- Do not assume "more RAAS blockade is better" - combining aliskiren with ACEis or ARBs increases harm rather than benefit
- Do not use in diabetic patients already on ACEi or ARB - this is an absolute contraindication 1
- Do not overlook the high-fat meal effect - absorption decreases by 71% (AUC) and 85% (Cmax) with high-fat meals, though clinical trials did not require fixed meal timing 1